MRK Add to watchlist $123.40 +2.62 (+2.17%) Last updated: Jul 15, 2026 15:19
52-Week Range
$123.40
$76.66 $123.40 $130.29

Fundamentals Overview

Merck & Co., Inc. is near the high of its 52-week range with premium valuation, trending upward today.

Valuation premium

P/E 34.1 P/B 6.65 P/S 4.65

Intrinsic value (DCF)

+63.6% upside vs price

Profitability

Net margin 13.6%

Risk (Beta)

0.21 — lower vol

Earnings & growth

EPS $3.61 Rev -0.2% Profit -243.1% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 67% confidence Risk: Lower Volatility — Beta 0.21. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +63.6% upside vs price · Analyst grade: B · Sentiment improving (3 upgrades)

Pressures (Sell):

3M vs S&P 500: -7.3%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$304.76B
P/E (TTM)
34.14
EPS (TTM)
$3.61
Dividend Yield
2.72%
52-Week Range
$76.66 - $130.29
Volume vs Avg
N/A
Beta
0.21

About

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhil...
Sector: Healthcare
Headquarters: US
Employees: 75,000
IPO Date: Jan 1978
Website: www.merck.com
Beta: 0.21 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 6, Equal Weight: 3, Hold: 3, Neutral: 6, Outperform: 4, Overweight: 6, Sector Outperform: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $201.82; current price is $123.40. That’s a +63.6% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 34.14
DCF value (model) $201.82 (63.6% upside)
PEG (TTM) N/A
P/B (TTM) 6.65
P/S (TTM) 4.65
P/FCF (TTM) 21.59
Liquidity & enterprise
Current Ratio (TTM) 1.3
Quick Ratio (TTM) 1.06
Cash Ratio (TTM) 0.2
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 13.62%
Gross margin (TTM) 75.91%
Operating margin (TTM) 27.59%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for MRK.

Analyst Sentiment at a Glance

B Sentiment Improving
Buy 6Equal Weight 3Hold 3Neutral 6Outperform 4Overweight 6Sector Outperform 2
3 upgrades, 0 downgrades
Price Target Consensus
Current $123.40
Median $142.00
Consensus $136.33
Low consensus $100.00
High consensus $155.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Morgan Stanley maintain Equal Weight Equal Weight 2026-07-09
RBC Capital maintain Outperform Outperform 2026-07-08
Wells Fargo maintain Overweight Overweight 2026-07-08
Cantor Fitzgerald maintain Neutral Neutral 2026-07-06
B of A Securities maintain Buy Buy 2026-06-30
Scotiabank maintain Sector Outperform Sector Outperform 2026-06-30
Wells Fargo maintain Overweight Overweight 2026-05-01
UBS maintain Buy Buy 2026-04-13
JP Morgan maintain Overweight Overweight 2026-04-06
RBC Capital maintain Outperform Outperform 2026-03-30
Citigroup maintain Neutral Neutral 2026-03-20
Wells Fargo maintain Overweight Overweight 2026-03-12
Freedom Broker maintain Hold Hold 2026-02-09
Guggenheim maintain Buy Buy 2026-02-06
Citigroup maintain Neutral Neutral 2026-02-04
Wells Fargo maintain Overweight Overweight 2026-02-04
Cantor Fitzgerald maintain Neutral Neutral 2026-02-04
Citigroup maintain Neutral Neutral 2026-01-27
TD Cowen maintain Hold Hold 2026-01-20
Wolfe Research upgrade Peer Perform Outperform 2026-01-08
Citigroup maintain Neutral Neutral 2026-01-07
UBS maintain Buy Buy 2026-01-07
BMO Capital upgrade Market Perform Outperform 2025-12-18
B of A Securities maintain Buy Buy 2025-12-15
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
Scotiabank maintain Sector Outperform Sector Outperform 2025-12-04
Goldman Sachs maintain Buy Buy 2025-12-02
Wells Fargo upgrade Equal Weight Overweight 2025-11-24
Deutsche Bank maintain Hold Hold 2025-11-18
Morgan Stanley maintain Equal Weight Equal Weight 2025-11-03